{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:02:43Z","timestamp":1775840563733,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12016-019-08775-4","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T08:02:57Z","timestamp":1578556977000},"page":"231-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4643-8609","authenticated-orcid":false,"given":"Aasha","family":"Harish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"8775_CR1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","volume":"180","author":"PG Woodruff","year":"2009","unstructured":"Woodruff PG, Modrek B et al (2009) T-helper type 2 driven inflammation defines major subphenotypes of asthma. Am J Crit Care Med 180:388\u2013395","journal-title":"Am J Crit Care Med"},{"key":"8775_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/17476348.2016.1111763","volume":"10","author":"I De Ferrari","year":"2016","unstructured":"De Ferrari I, Chiappori A et al (2016) Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? Expert Rev Respir Med 10:9\u201338","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"8775_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.183.1.195","volume":"183","author":"PS Foster","year":"1996","unstructured":"Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG (1996) Interleukin 5 deficiency abolishes eosinophilia, airways hyperactivity, and lung damage in a mouse asthma model. J Exp Med 183(1):195\u2013201","journal-title":"J Exp Med"},{"issue":"1","key":"8775_CR4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1164\/ajrccm.157.1.9703027","volume":"157","author":"HZ Shi","year":"1998","unstructured":"Shi HZ, Xiao CQ, Zhong D, Qin SM, Liu Y, Liang GR, Xu H, Chen YQ, Long XM, Xie ZF (1998) Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med 157(1):204\u2013209","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"8775_CR5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1586\/eci.11.27","volume":"74","author":"JP Abonia","year":"2001","unstructured":"Abonia JP, Putnam PE (2001) Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol 74(4):411\u2013417","journal-title":"Expert Rev Clin Immunol"},{"key":"8775_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2017.00135","volume":"4","author":"D Bagnasco","year":"2017","unstructured":"Bagnasco D, Ferrando M, Varrichi G et al (2017) Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, future perspectives in severe eosinophilic asthma. Frontiers in Medicine 4:1\u201310","journal-title":"Frontiers in Medicine"},{"issue":"5","key":"8775_CR7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","volume":"132","author":"M Laviolette","year":"2013","unstructured":"Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R et al (2013) Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132(5):1086\u201396.e5","journal-title":"J Allergy Clin Immunol"},{"key":"8775_CR8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, Peng L et al (2010) MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125:1344\u20131353","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8775_CR9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1517\/14712598.2012.642359","volume":"12","author":"A Ghazi","year":"2011","unstructured":"Ghazi A, Trikha A, Calhoun WJ (2011) Benralizumab\u2014a humanized mAb to IL-5R\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity\u2014a novel approach for the treatment of asthma. Expert Opin Biol Ther 12(1):113\u2013118","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"8775_CR10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","volume":"3","author":"F Legrand","year":"2015","unstructured":"Legrand F, Klion A (2015) Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol: In Practice 3(2):167\u2013174","journal-title":"J Allergy Clin Immunol: In Practice"},{"issue":"3","key":"8775_CR11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","volume":"130","author":"P Velent","year":"2012","unstructured":"Velent P, Klion AD et al (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130(3):607","journal-title":"J Allergy Clin Immunol"},{"key":"8775_CR12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2014.01.018","volume":"48-49","author":"L Mouthon","year":"2014","unstructured":"Mouthon L, Donogue B et al (2014) Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named as Churg Strauss syndrome). J Autoimmun 48-49:99\u2013103","journal-title":"J Autoimmun"},{"issue":"8","key":"8775_CR13","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094","journal-title":"Arthritis Rheum"},{"issue":"12","key":"8775_CR14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenburg","year":"2008","unstructured":"Rothenburg ME et al (2008) Treatment of patients with hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215\u20131228","journal-title":"N Engl J Med"},{"issue":"4","key":"8775_CR15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","volume":"126","author":"F Roufosse","year":"2010","unstructured":"Roufosse F, de Lavareille A, Schanden\u00e9 L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A (2010) Mepolizumab as a corticosteroid sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 126(4):828\u2013835","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8775_CR16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","volume":"131","author":"FE Roufosse","year":"2013","unstructured":"Roufosse FE et al (2013) Long-term safety mepolizumab for treatment of hypereosinophilic syndrome. J Allergy Clin Immunol 131(2):461\u2013467","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8775_CR17","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","volume":"121","author":"ML Stein","year":"2008","unstructured":"Stein ML, Villanueva JM, Buckmeier BK et al (2008) Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 121(6):1473\u20131483","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8775_CR18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jpeds.2009.01.058","volume":"155","author":"S Mehr","year":"2009","unstructured":"Mehr S, Rego S, Kakakios A, Kilham H, Kemp A (2009) Treatment of a case of pediatric hypereosinophilic syndrome with anti-IL-5. J Pediatr 155(2):289\u2013291","journal-title":"J Pediatr"},{"key":"8775_CR19","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). July 19, 2016. Identifier NCT02836496. Study 200622: a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic syndrome"},{"issue":"8","key":"8775_CR20","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","volume":"103","author":"AD Klion","year":"2004","unstructured":"Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB (2004) Safety and efficacy of monoclonal IL-5 ab SCH55700 in treatment of patients with hypereosinophilic syndrome. Blood 103(8):2939\u20132941","journal-title":"Blood"},{"key":"8775_CR21","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"Kuang","year":"2019","unstructured":"Kuang et al (2019) Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med 380:1336\u20131346","journal-title":"N Engl J Med"},{"issue":"6","key":"8775_CR22","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","volume":"118","author":"M Stein","year":"2006","unstructured":"Stein M, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assa'ad AH, Rothenberg ME (2006) Anti IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118(6):1312\u20131319","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8775_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","volume":"59","author":"A Straumann","year":"2010","unstructured":"Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU (2010) Anti-interleukin 5 antibody treatment (mepolizumab) in active eosinophilic esophagitis: a randomized placebo-controlled double blind trial. Gut 59(1):21\u201330","journal-title":"Gut"},{"issue":"1","key":"8775_CR24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaci.2010.04.029","volume":"126","author":"S Conus","year":"2010","unstructured":"Conus S, Straumann A, Bettler E, Simon HU (2010) Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis. J Allergy Clin Immunol 126(1):175\u2013177","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8775_CR25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","volume":"141","author":"AH Assa\u2019ad","year":"2011","unstructured":"Assa\u2019ad AH et al (2011) An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141(5):1593\u201315604","journal-title":"Gastroenterology"},{"issue":"6","key":"8775_CR26","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jaci.2013.02.042","volume":"131","author":"M Otani","year":"2013","unstructured":"Otani M et al (2013) Anti-IL-5 therapy rescues mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 131(6):1576\u20131582","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8775_CR27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaci.2011.11.044","volume":"129","author":"JM Spergel","year":"2012","unstructured":"Spergel JM et al (2012) Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double blind randomized placebo-controlled trial. J Allergy Clin Immunol 129(2):4","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8775_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","volume":"125","author":"JE Kahn","year":"2010","unstructured":"Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, Bl\u00e9try O (2010) Sustained response to mepolizumab in refractory Churg Strauss syndrome. J Allergy Clin Immunol 125(1):267\u2013270","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8775_CR29","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME (2010) Mepolizumab as steroid sparing treatment option in patient with Churg Strauss syndrome. J Allergy Clin Immunol 125(6):1336\u20131343","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8775_CR30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B (2011) Targeting interleukin 5 in refractory and relapsing Churg Strauss syndrome. Ann Intern Med 155(5):341\u2013343","journal-title":"Ann Intern Med"},{"issue":"1 supp 70","key":"8775_CR31","first-page":"s62","volume":"20","author":"K Hermann","year":"2012","unstructured":"Hermann K et al (2012) Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg Strauss syndrome. Clin Exp Rheumatol 20(1 supp 70):s62\u2013s65","journal-title":"Clin Exp Rheumatol"},{"issue":"20","key":"8775_CR32","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Weschler","year":"2017","unstructured":"Weschler ME et al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376(20):1921\u20131932","journal-title":"N Engl J Med"},{"key":"8775_CR33","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 October 28. Identifier NCT02947945. Reslizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Study"},{"key":"8775_CR34","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 January 5. Identifier NCT03020436. Benralizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Study"},{"issue":"5","key":"8775_CR35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ajg.2013.71","volume":"108","author":"ES Dellon","year":"2013","unstructured":"Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA, American College of Gastroenterology (2013) ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 108(5):679\u201392; quiz 693","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"8775_CR36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","volume":"113","author":"JK Garrett","year":"2004","unstructured":"Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME (2004) Anti-interleukin 5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113(1):115\u2013119","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"8775_CR37","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","volume":"349","author":"SG Plotz","year":"2003","unstructured":"Plotz SG et al (2003) Use of anti-IL-5 ab in Hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349(24):2334\u20132339","journal-title":"N Engl J Med"},{"issue":"4","key":"8775_CR38","doi-asserted-by":"crossref","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","volume":"52","author":"T Volmer","year":"2018","unstructured":"Volmer T et al (2018) Consequences of long term oral corticosteroid therapy and its side-effect in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J 52(4):1800703","journal-title":"Eur Respir J"},{"issue":"5","key":"8775_CR39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","volume":"42","author":"LH Fraiser","year":"1991","unstructured":"Fraiser LH, Kanekal S, Kehrer JP (1991) Cyclophosphamide toxicity. Drugs 42(5):781\u2013795","journal-title":"Drugs"},{"issue":"11","key":"8775_CR40","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","volume":"69","author":"X Pu\u00e9chal","year":"2017","unstructured":"Pu\u00e9chal X et al (2017) Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized. Control Trial Arthritis Rheumatolol 69(11):2175\u20132186","journal-title":"Control Trial Arthritis Rheumatolol"},{"issue":"3","key":"8775_CR41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.iac.2007.07.006","volume":"27","author":"AD Klion","year":"2007","unstructured":"Klion AD (2007) Approach to the therapy of Hypereosinophilic syndrome. Immunol Allergy Clin N Am 27(3):551\u2013560","journal-title":"Immunol Allergy Clin N Am"},{"issue":"6","key":"8775_CR42","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1016\/S0016-5085(18)31195-8","volume":"154","author":"ES Dellon","year":"2018","unstructured":"Dellon ES et al (2018) Efficacy and Safety of Rpc4046, an anti-interleukin 13 monoclonal antibody, in patients with active eosinophilic esophagitis: analysis of the steroid refractory subgroup from the heroes study. Gastroenterology 154(6):S244","journal-title":"Gastroenterology"},{"issue":"2","key":"8775_CR43","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","volume":"135","author":"ME Rothenberg","year":"2015","unstructured":"Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A, Jones I, Arm JP, Strieter RM, Sabo R, Gunawardena KA (2015) Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 135(2):500\u2013507","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8775_CR44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2018-06-851600","volume":"132","author":"GJ Gleich","year":"2018","unstructured":"Gleich GJ (2018) Dexpramipexole: a new antieosinophil drug? Blood 132(5):461\u2013462","journal-title":"Blood"},{"issue":"5","key":"8775_CR45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","volume":"132","author":"SR Panch","year":"2018","unstructured":"Panch SR, Bozik ME, Brown T, Makiya M, Prussin C, Archibald DG, Hebrank GT, Sullivan M, Sun X, Wetzler L, Ware J, Fay MP, Dunbar CE, Dworetzky SI, Khoury P, Maric I, Klion AD (2018) Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood 132(5):501\u2013509","journal-title":"Blood"},{"issue":"2","key":"8775_CR46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","volume":"3","author":"F Legrand","year":"2015","unstructured":"Legrand F, Klion A (2015) Biologic therapies targeting Eosinophils: current status and future prospects. J Allergy Clin Immunol: In Practice 3(2):167\u2013174","journal-title":"J Allergy Clin Immunol: In Practice"},{"key":"8775_CR47","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 April 12. Identifier NCT03496571. A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of AK002 in patients with eosinophilic gastritis and\/or eosinophilic gastroenteritis"}],"updated-by":[{"DOI":"10.1007\/s12016-020-08781-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000}}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-019-08775-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-019-08775-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-019-08775-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:24:48Z","timestamp":1610065488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-019-08775-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["8775"],"URL":"https:\/\/doi.org\/10.1007\/s12016-019-08775-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12016-020-08781-x","asserted-by":"object"}]},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"9 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake in the fifth paragraph of the \u201cConclusion\u201d section.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Author Aasha Harish, MD, MPH declares that she does not have any conflict of interest. Author Stanley Schwartz, MD, PhD received a speaker honorarium from Takeda Pharmaceutical Co and CSL Behring and owns stock in Pfizer Pharmaceutical Co and Merck Pharmaceutical Co.Research with animals and human subjects: This article does not contain any studies with human participants or animals performed by any of the authors.Informed consent: This authors of this article were not involved in the enrollment of subjects used of studies reported. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}